Dr Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Inc., USA, a wholly owned subsidiary of the Company, has successfully completed the sale of all issued and outstanding membership interests in its wholly owned subsidiary viz; Dr. Reddy's Laboratories Louisiana LLC, including the manufacturing facility located in Shreveport, Louisiana, USA, on March 21, 2025. Consequently, Dr. Reddy's Laboratories Louisiana LLC has ceased to be a wholly owned subsidiary of Dr. Reddy's Laboratories Inc. and a step-down wholly owned subsidiary of Dr. Reddy's Laboratories effective from 21 March 2025. Powered by Capital Market - Live

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 9 May 2025.Powered by Capital Market - Live

Dr. Reddy's Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/mL) single-dose infusion bags to the consumer level, in the United States. The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL. Powered by Capital Market - Live

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powered by Capital Market - Live

The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and confirmed that the inspection is now closed. According to a filing with the exchange dated 19 November 2024, the inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issued a Form 483 with seven observations during the inspection, which the company has committed to addressing within the stipulated timeline. Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products. The pharma company reported 2.4% increase in consolidated net profit to Rs 1,413.70 crore in Q3 FY25 compared with Rs 1,380.90 crore in Q3 FY24. Net sales jumped 15.9% to Rs 8,358.60 crore in Q3 FY25 compared with Rs 7,214.80 crore in Q3 FY24. The scrip rose 0.20% to Rs 1,128.80 on the BSE. Powered by Capital Market - Live

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fully paid up, on 14 February 2025, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy's Employees Stock Options Scheme, 2002. Powered by Capital Market - Live

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1241.5, up 1.14% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.41% on the day, quoting at 23600.05. The Sensex is at 77920.62, down 0.45%. Dr Reddys Laboratories Ltd has slipped around 8.14% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has slipped around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 13.75 lakh shares today, compared to the daily average of 20.88 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 1237.6, up 1.05% on the day. Dr Reddys Laboratories Ltd is up 0.45% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.The PE of the stock is 19.77 based on TTM earnings ending December 24.Powered by Capital Market - Live

Dr Reddys Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 1176.75, down 0.38% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.71% on the day, quoting at 23121.1. The Sensex is at 76421.63, up 0.69%.Dr Reddys Laboratories Ltd has eased around 14.54% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has eased around 9.36% in last one month and is currently quoting at 20796.6, up 1.29% on the day. The volume in the stock stood at 22.62 lakh shares today, compared to the daily average of 20.2 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1182.5, up 0.81% on the day. Dr Reddys Laboratories Ltd jumped 0.73% in last one year as compared to a 7.43% rally in NIFTY and a 20.58% spurt in the Nifty Pharma index.The PE of the stock is 18.99 based on TTM earnings ending December 24.Powered by Capital Market - Live

The key equity indices pared all their gains and traded in negative territory in afternoon trade. The Nifty slipped below the 23,200 level after hitting the day's high of 23,347.30 in the early afternoon trade. Pharma, media and auto shares declined while FMCG and IT stocks advanced. At 13:25 IST, the barometer index, the S&P BSE Sensex, shed 45.42 points or 0.07% to 76,474.96. The Nifty 50 index gained 20.60 points or 0.09% to 23,184.75. In the broader market, the S&P BSE Mid-Cap index declined 1.06% and the S&P BSE Small-Cap index fell 1.43%. The market breadth was weak. On the BSE, 1,188 shares rose and 2,629 shares fell. A total of 136 shares were unchanged. Economy: The HSBC Flash India Composite Output Index, which measures the month-on-month change in the combined output of India's manufacturing and service sectors, fell from a final reading of 59.2 in December to 57.9 in January. This indicated the weakest rate of expansion in 14 months. However, the headline figure remained well above its long-term average of 54.7. While the slowdown at the composite level, driven by the service sector, was evident, there was a pickup in growth among goods producers. The HSBC Flash India Manufacturing PMI, a snapshot of factory business conditions based on new orders, output, employment, supplier delivery times, and stocks of purchases, rose from 56.4 in December to 58.0 in January, reflecting the best improvement in the sector's health since July 2024. Pranjul Bhandari, Chief India Economist at HSBC, said: 'India's manufacturing sector started the year strong, with output and new orders bouncing back from a relatively weak third fiscal quarter. The rise in new export orders was especially noticeable, and the easing of input cost inflation is also good news for manufacturers. The cooling in growth in new domestic business in the services sector, however, highlights a potentially emerging weak spot in the economy. New export business for service providers, on the other hand, looks set to maintain its growing momentum.' Gainers & Losers: Eicher Motors (up 2%), Tata Conusmer Products (up 1.80%), Hindustan Unilever (up 1.65%), Power Grid Corporation of India (up 1.56%) and Grasim Industries (up 1.54%) were the major Nifty gainers. Dr Reddy Laboratories (down 4.91%), Trent (down 2.53%), Apollo Hospital Enterprise (down 1.90%), Mahindra & Mahindra (down 1.78%) and Cipla (down 1.68%) were the major Nifty losers. Dr Reddy's Laboratories dropped 4.54%. The company reported 2.4% increase in consolidated net profit to Rs 1,413.70 crore in Q3 FY25 compared with Rs 1,380.90 crore in Q3 FY24. Net sales jumped 15.9% to Rs 8,358.60 crore in Q3 FY25 as compared with Rs 7,214.80 crore in Q3 FY24. The media reports highlighting concerns over the declining revenue contribution from Revlimid, which has also pressured margins. Revlimid, a blockbuster cancer drug and a significant growth driver for Dr. Reddy's in recent years, is nearing its patent expiry in January 2026, raising fears of a potential revenue decline post-expiry. A foreign brokerage noted that while the launch of the anti-diabetic drug Semaglutide in Canada in early 2026 could offer some relief to Dr. Reddy's, it is unlikely to fully compensate for the revenue loss from Revlimid. While Dr. Reddy's management has identified other growth drivers, the brokerage believes that Semaglutide will primarily fuel growth in the short term, with other long-term factors expected to contribute later. Stocks in Spotlight: Amber Enterprises India added 3.55% after the company reported consolidated net profit of Rs 35.87 crore in Q3 FY25, compared with net loss of Rs 0.48 crore posted in Q3 FY24. Revenue from operations jumped 64.8% year on year (YoY) to Rs 2,133.33 crore in the quarter ended 31 December 2024. United Spirits fell 1.14%. The spirits maker's standalone net profit jumped 36.31% to Rs 473 crore in Q3 FY25 as against Rs 347 crore posted in Q3 FY24. Revenue from operations (excluding excise duty) stood at Rs 3,432 crore in Q3 FY25, up 14.82% YoY, mainly driven by resilient consumer demand in peak festive season and a fast scale-up in Andhra Pradesh. Capri Global Capital (CGCL) rallied 12.01% after the NBFC's consolidated net profit surged 88.41% to Rs 128.08 crore on 35.63% increase in total income to Rs 821.83 crore in Q3 FY25 over Q3 FY24. Mankind Pharma fell 3.77% after the company's consolidated net profit declined 16.2% to Rs 380.23 crore in Q3 FY25 as against Rs 453.76 crore posted in Q3 FY24. However, revenue from operations increased 23.9% year on year (YoY) to Rs 3,230 crore in the third quarter of FY25. V2 Retail hit the upper circuit of 5% after the company's consolidated net profit surged 117.2% to Rs 51.19 crore in Q3 FY25 compared with Rs 23.57 crore in Q3 FY24. Revenue from operations jumped 58.1% to Rs 590.94 crore in Q3 FY25 compared with Rs 373.76 crore in corresponding quarter last year. Sona BLW Precision Forgings declined 3.11%. The company reported a 13.93% increase in consolidated net profit to Rs 151.19 crore on 11.02% rise in revenue from operations to Rs 867.91 crore in Q3 FY25 over Q3 FY24. Thyrocare Technologies dropped 1.03%. The healthcare service provider reported 28.56% increase in consolidated net profit to Rs 18.95 crore on 23.14% rise in revenue from operations to Rs 165.92 crore in Q3 FY25 over Q3 FY24. Global Markets: European market advanced as US President Donald Trump called for lower interest rates and cheaper oil prices, additionally investors are also likely to be looking ahead to the Fed's FOMC meeting on Wednesday with no change expected to interest rates. Asian market traded mixed on Friday as the Bank of Japan raised its key short-term interest rate to around 0.5%, the highest in 17 years, in an effort to further normalize its monetary policy as inflation remains within target levels. Inflation in Japan stayed on track in December, supporting the case for the BoJ's expected interest rate hike. Core CPI, excluding volatile fresh food prices, rose 3% year-on-year, as widely expected. Headline CPI hit 3.6% y-o-y'a two-year high'up from 2.9% in November. On the downside, Japanese manufacturing activity contracted further in January. The au Jibun Bank Manufacturing PMI dropped to 48.8 from December's 49.6, marking the seventh consecutive month of contraction. Any reading below 50 signals a shrinking sector. Chinese equities climbed after U.S. President Donald Trump suggested he would prefer not to impose further tariffs on China during a media interview, easing trade war tensions. In the U.S., the S&P 500 closed at a record 6,118.72 points on Thursday, up 0.5%. The Dow Jones Industrial Average gained 0.9% to 44,565.26, while the NASDAQ Composite edged up 0.2%. Investors responded positively to robust corporate earnings and Trump's address at Davos, where he urged for immediate global interest rate cuts. GE Aerospace shares soared 6.6% after posting better-than-expected Q4 sales and profits. Union Pacific Corporation saw a 5.2% jump in stock price, fueled by strong operational metrics and lower fuel costs. On the flip side, Electronic Arts Inc. tumbled 16.7% after slashing its net bookings guidance, citing weak performance in several games, particularly its soccer franchise. American Airlines Group slid 8.7% as it projected a larger-than-expected Q1 loss due to rising costs, despite exceeding Q4 earnings forecasts. President Trump, speaking remotely at the World Economic Conference in Davos, Switzerland, addressed global economic issues including interest rates, U.S.-China trade, and energy policies. On monetary policy, he urged for immediate interest rate cuts worldwide, emphasizing their importance for economic growth.Powered by Capital Market - Live

Net sales jumped 15.9% to Rs 8,358.60 crore in Q3 FY25 as compared with Rs 7,214.80 crore in Q3 FY24. The stock dropped 4.54% to Rs 1,230.80 amid media reports highlighting concerns over the declining revenue contribution from Revlimid, which has also pressured margins. Revlimid, a blockbuster cancer drug and a significant growth driver for Dr. Reddy's in recent years, is nearing its patent expiry in January 2026, raising fears of a potential revenue decline post-expiry. A foreign brokerage noted that while the launch of the anti-diabetic drug Semaglutide in Canada in early 2026 could offer some relief to Dr. Reddy's, it is unlikely to fully compensate for the revenue loss from Revlimid. While Dr. Reddy's management has identified other growth drivers, the brokerage believes that Semaglutide will primarily fuel growth in the short term, with other long-term factors expected to contribute later. Profit before tax (PBT) rose 2.5% YoY to Rs 1874.30 crore in Q3 FY25. EBITDA stood at Rs 2298.2 crore inQ3 FY25, registering the growth of 8.88% as compared with Rs 2110.7 crore in Q3 FY24. EBITDA margin declined to 27.5% in Q3 FY25 as compared with Rs 29.3% in Q3 FY24. Selling, general & administrative (SG&A) expenses for Q2 FY25 were at Rs 2,410 crore, YoY increase of 19%. Research & development (R&D) expenses in third quarter of FY25 stood at Rs 670 crore, 8% of revenue. During the quarter, revenues from emerging markets segment stood at Rs 1,440 crore, year on year increase of 12%, growth is attributable to market share expansion as well as new product launches. Revenues from India market during the quarter stood at Rs 1,350 crore, year on year increase of 14%, Growth was led by revenues from the in-licensed vaccine portfolio, new product launches as well as price increases, partially offset by lower volume pick-up in certain brands in Cardiac and Gastrointestinal therapy areas. Revenues from the North American market stood at Rs 3,380 crore, reflecting a 1% year-on-year increase. This growth was driven by higher volumes, new product launches, and favorable foreign exchange movements. However, these gains were partially offset by price erosion compared to the previous year. During the quarter, revenue from Europe market was at Rs 1,210 crore, year on year growth of 143%. The growth includes revenues from the recently acquired NRT portfolio. Underlying growth excluding NRT is 22% YoY. Revenues from Global Generics (GG) during the quarter grew 17% YoY to Rs 7,380 crore, growth was largely driven by revenues from the acquired NRT portfolio, higher volumes and new product launches. Revenues from Pharmaceutical Services and Active Ingredients (PSAI) rose 19.51% to Rs 840.70 crore in Q2 FY25, mainly driven by momentum in base business volumes, growth in services business and revenues from new products. Commenting on the results, Co-Chairman & MD, G V Prasad said, 'We delivered double digit growth aided by our newly acquired NRT business, new launches and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability and innovation.' Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.Powered by Capital Market - Live